Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I MAD Study of Globalagliatin in T2DM
NCT03414892Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Globalagliatin Hydrochloride (SY-004) with Placebo (2 arms). Primary endpoint: Mean change in glucose area under curve (AUC) from baseline at 28 days. Started Jan 2018; status: completed.
02
Drugs
globalagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03414892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414892.